The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
XPD and XRCC1 Genetic Polymorphisms Are Prognostic Factors in Advanced Non—Small-Cell Lung Cancer Patients Treated With Platinum Chemotherapy
Open accessAbstract
Purpose: Platinum agents cause DNA cross-linking and oxidative damage. Genetic polymorphisms of DNA repair genes are associated with differential DNA repair activity and may explain interindividual differences in overall survival after therapy with platinum agents for non–small-cell lung cancer (NSCLC). Methods: We used polymerase chain reaction–restriction fragment length polymorphism to evaluate genetic polymorphisms of the XPD (Asp312Asn) and XRCC1 (Arg399Gln) DNA repair genes in 103 patients with stage III (54%) and IV (46%) NSCLC treated with platinum-based chemotherapy. Results: Median age was 58 years (range, 32 to 77 years), 49% were females, and there were 86 deaths. Median follow-up period was 61.9 months. Median survival time (MST) was 14.9 months; by stage, MST was 28.6 months (IIIA), 16.0 months (IIIB), and 9.3 months (IV). Genotypes were not associated with stage. Increasing numbers of either XPD or XRCC1 variant alleles were associated with shorter overall survival (P = .003 and P = .07, respectively, by log-rank test). Similarly, when we compared combinations of variant alleles across both polymorphisms, we found that a greater number of variant alleles was associated with decreasing overall survival (P = .009, log-rank test). These polymorphisms independently predicted overall survival even after taking into account stage, performance status, and chemotherapy regimen. Conclusion: Genetic polymorphisms in XPD and XRCC1 may be important prognostic factors in platinum-treated patients with advanced NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Thomas, A., Murray, T., & Thun, M. (2002) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.52.1.23 · Cited by 2,917
Non-small Cell Lung Cancer Collaborative Group (1995) · BMJ · doi:10.1136/bmj.311.7010.899 · Cited by 2,850
Estimates of the worldwide incidence of eighteen major cancers in 1985
Parkin, D. M., Pisani, P., & Ferlay, J. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910540413 · Cited by 1,638
How nucleotide excision repair protects against cancer
Friedberg, E. C. (2001) · Nature Reviews Cancer · doi:10.1038/35094000 · Cited by 730
Rapp, E., Pater, J. L., Willan, A., Cormier, Y., Murray, N., Evans, W. K., Hodson, D. I., Clark, D. A., Feld, R., & Arnold, A. M. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.4.633 · Cited by 698
Nucleotide excision repair and human syndromes
de Boer, J., & Hoeijmakers, J. H. J. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.453 · Cited by 674
Pisani, P., Parkin, D. M., & Ferlay, J. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910550604 · Cited by 583
Wei, Q. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.21.1764 · Cited by 507
Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients.
Spitz, M. R., Wu, X., Wang, Y., Wang, L.-E., Shete, S. S., Amos, C. I., Guo, Z., Lei, L., Mohrenweiser, H. W., & Wei, Q. (2001) · PubMed · Cited by 489
Duell, E. J. (2000) · Carcinogenesis · doi:10.1093/carcin/21.5.965 · Cited by 447
XPD polymorphisms: effects on DNA repair proficiency
Lunn, R. M., Helzlsouer, K. J., Parshad, R., Umbach, D. M., Harris, E. L., Sanford, K. K., & Bell, D. A. (2000) · Carcinogenesis · doi:10.1093/carcin/21.4.551 · Cited by 431
Furuta, T., Ueda, T., Aune, G. J., Sarasin, A. R., Kraemer, K. H., & Pommier, Y. G. (2002) · PubMed · Cited by 422
Cancer Chemotherapy and Biotherapy: Principles and Practice
Chabner, B. A., & Longo, D. L. (1996) · Cited by 409
Bunn, P. A., & Kelly, K. L. (1998) · PubMed · Cited by 400
Molecular mechanisms involved in cisplatin cytotoxicity
Jordan, P., & Carmo-Fonseca*, M. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000762 · Cited by 398
Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy
Reed, E. (1998) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(98)90056-1 · Cited by 397
Clinical Perspectives on Platinum Resistance
Giaccone, G. (2000) · Drugs · doi:10.2165/00003495-200059004-00002 · Cited by 364
Genetic polymorphisms in DNA repair genes and risk of lung cancer
Butkiewicz, D., Rusin, M., Enewold, L., Shields, P. G., Chorazy, M., & Harris, C. C. (2001) · Carcinogenesis · doi:10.1093/carcin/22.4.593 · Cited by 314
Human xeroderma pigmentosum group D gene encodes a DMA helicase
Sung, P., Bailly, V., Weber, C., Thompson, L. H., Prakash, L., & Prakash, S. (1993) · Nature · doi:10.1038/365852a0 · Cited by 311
Reduced DNA repair capacity in lung cancer patients.
Wei, Q., Cheng, L., Hong, W. K., & Spitz, M. R. (1996) · PubMed · Cited by 299
Molecular abnormalities in lung cancer.
Salgia, R., & Skarin, A. T. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.1207 · Cited by 276
Travis, W. D., Lubin, J., Ries, L., & Devesa, S. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960615)77:12<2464::aid-cncr8>3.0.co;2-m · Cited by 254
[Molecular abnormalities in lung cancer].
Shimizu, S., & Mitsudomi, T. (2002) · PubMed · Cited by 235
Reed, E., Ozols, R. F., Tarone, R., Yuspa, S. H., & Poirier, M. C. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.14.5024 · Cited by 217
DNA repair and cisplatin resistance in non-small-cell lung cancer
Rosell, R., Lord, R. V. N., Taron, M., & Reguart, N. (2002) · Lung Cancer · doi:10.1016/s0169-5002(02)00224-6 · Cited by 178
An Analysis of DNA Repair as a Determinant of Survival in Patients With Non-Small-Cell Lung Cancer
Bosken, C. H. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.14.1091 · Cited by 169
TFIIH: a key component in multiple DNA transactions
Hoeijmakers, J. H. J., Egly, J.-M., & Vermeulen, W. (1996) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(96)90006-4 · Cited by 161
Cheng, L., Spitz, M. R., Hong, W. K., & Wei, Q. (2000) · Carcinogenesis · doi:10.1093/carcin/21.5.527 · Cited by 150
DNA Repair: a Double-Edged Sword
Wei, Q., Frazier, M. L., & Levin, B. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.6.440 · Cited by 144
Pharmacogenetics and cancer chemotherapy
Iyer, L., & Ratain, M. J. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00230-5 · Cited by 105
Do Molecular Markers Predict Survival in Non–Small-Cell Lung Cancer?
Greatens, T. M., Niehans, G. A., Rubins, J. B., Jessurun, J., Kratzke, R. A., Maddaus, M. A., & Niewoehner, D. E. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.4.9707108 · Cited by 104
Camps, C., Sarries, C., Roig, B., et al. (2003) · Clinical Lung Cancer · doi:10.3816/clc.2003.n.004 · Cited by 54
Stephens, R. J., Brown, J. M., Fairlamb, D. J., Gower, N. H., Maslove, L., Milroy, R., Napp, Peake, Rudd, R., Spiro, S. G., et al. (2002) · UCL Discovery (University College London) · Cited by 50
Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer
Sarries, C., Haura, E. B., Roig, B., Tarón, M., Abad, A., Scagliotti, G. V., & Rosell, R. (2002) · Pharmacogenomics · doi:10.1517/14622416.3.6.763 · Cited by 42
Cited by
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E., & Adjei, A. A. (2008) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60735-0 · Cited by 3,908
The role of apoptosis in cancer development and treatment response
Brown, J. M., & Attardi, L. D. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1560 · Cited by 944
Isla, D., Sarries, C., Rosell, R., Alonso, G., Domine, M., Taron, M., Lopez-Vivanco, G., Camps, C., Botia, M., Nuñez, L., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh319 · Cited by 294
DNA Repair Pathways in Clinical Practice: Lessons From Pediatric Cancer Susceptibility Syndromes
Kennedy, R. D., & D'Andrea, A. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4171 · Cited by 286
Moreno, V., Gemignani, F., Landi, S., Gioia-Patricola, L., Chabrier, A., Blanco, I., González, S., Guino, E., Capellà, G., Canzian, F., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1363 · Cited by 254
Metadata
- Authors
- Gurubhagavatula, S., Liu, G., Park, S., Zhou, W., Su, L., Wain, J. C., Lynch, T. J., Neuberg, D. S., & Christiani, D. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-07-01
- Volume
- 22
- Issue
- 13
- Pages
- 2594-2601
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2118951956
- Cited by
- 292
- References
- 35
- FWCI
- 18.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.